However, the first domestic research ...

Current views on the issue of NRT What are the current views on the issue of NRT in cardiovascular disease? World experience shows that smoking cessation - one of the major measures of primary and secondary prevention - reduces morbidity and mortality, even among those who had quit smoking before the development of cardiac pathology [12]. In addition, it can significantly reduce health care costs, particularly for the treatment coronary artery disease [13, 14]. Unfortunately, even in Europe, where the situation with smoking is less critical than in Russia, every fifth patient, hospitalized on the coronary heart disease (aorto_koronarnoe bypass surgery, angioplasty, acute myocardial infarction) continues to smoke [15], not being able to overcome nicotine addiction independently without the psychological and medical support. Safety of NRT in patients with stable CVD proved a lot of research [16]. That people with heart disease rejection of cigarettes bring special benefit: a high risk of cardiovascular complications in case of continuation of smoking rapidly decreases after the rejection of the habit [20]. The recommendations of the Ontario Medical Association writes: "For patients with heart disease are much more dangerous to continue smoking than to use NRT. People with cardiovascular disease who are unable to quit on their own, primarily to recommend NRT [20]. Adhere to the same position the authors guide to NRT in patients with CVD, was recently published in the UK [21]. According to the latest WHO recommendations, NRT is recommended for patients with stable CVD, previously unsuccessfully attempt to quit smoking. In this case, the appointment of NRT is solved in conjunction with the attending physician if the patient within the previous 4 weeks. suffered a serious cardiovascular event (stroke, myocardial infarction, an episode of unstable angina, cardiac arrhythmia, bypass surgery or angioplasty) or suffers from uncontrolled hypertension. Patients with stable CVD NRT is not contraindicated. This position as soon as possible should be reflected in clinical guidelines, and in the information leaflet for patients. Soon as the results of new studies on the safety of NRT in an unstable, or severe acute course of CVD. In Russia, the NRT products have appeared in the free sale of more than 5 years ago. However, the first domestic study of the efficacy and safety of NRT to-date evidence-based medicine is carried out only now, on the basis of a specialized office for the prevention and treatment of tobacco dependence of the State Research Center of Preventive Medicine of the Russian Federation. The final results will be available next year, because to talk about long-term effectiveness of any method of assistance in quitting smoking is possible only after 12 months of therapy.